OAM
EIDX

Oppenheimer Asset Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Oppenheimer Asset Management’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,607
Closed -$150K – 1694
2019
Q4 		$150K Sell
2,607
-1,558
-37% -$77.1K ﹤0.01% 1117
2019
Q3 		$150K Sell
4,165
-45
-1% -$1.76K ﹤0.01% 1101
2019
Q2 		$131K Sell
4,210
-713
-14% -$19.3K ﹤0.01% 1167
2019
Q1 		$115K Sell
4,923
-2,639
-35% -$42.3K ﹤0.01% 1174
2018
Q4 		$104K Buy
+7,562
New +$95.4K ﹤0.01% 1178

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Oppenheimer Asset Management's EIDX Position: Q1 2020 in Review

Oppenheimer Asset Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2020, closing a stake of 2,607 shares — an estimated $150K sold.

Oppenheimer Asset Management first reported a position in EIDX in Q4 2018 and held it in 5 quarters. The position peaked at $150K in Q4 2019. 89 funds tracked by Wall St. Rank hold EIDX as of Q1 2020.

  • Oppenheimer Asset Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Oppenheimer Asset Management sold 2,607 Eidos Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $150K.
  • Oppenheimer Asset Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2018 and held it in 5 quarters.
  • Oppenheimer Asset Management's Eidos Therapeutics, Inc. Common Stock position peaked at $150K in Q4 2019.
  • 89 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Oppenheimer Asset Management's 13F filing for Q1 2020, filed 8 May 2020.